Intestinal Levodopa/Carbidopa Infusion as a Therapeutic Option for Unresponsive Freezing of Gait after Deep Brain Stimulation in Parkinson’s Disease

Table 2

Characteristic of the treatment with LCIG and levodopa-equivalent doses in the five patients.

Patient	Age at the time of LCIG (years)	LED pre-LCIG (mg)	LED post-LCIG (LCIG + CR) 1st month (mg)	LED post-LCIG (LCIG + CR) 12 months (mg)	DBS ON/OFF at 12 months	Daily time spent in OFF after LCIG (UPDRS Item 39)	Functional impact of dyskinesias after LCIG (UPDRS item 33)
P1	71	2250	2164	2310	OFF	1	1
P2	70	2400	2130	1960	OFF	1	1
P3	59	855	1233	1098	ON	1	1
P4	70	885	1638	1914	ON	1	1
P5	66	1874	2100	NA	ON	NA	NA

Median age (years) at the time of LCIG: 66 IQR (59–71). Median LED (mg) pre-LCIG: 1874 IQR (855–2400). Median LED (mg) post-LCIG after 1 month: 2100 IQR (1233–2164). Median LED (mg) post-LCIG after 12 months: 1937 IQR (1098–2310). LED pre-LCIG = total equivalent dose of levodopa oral medication; LED post-LCIG = total equivalent dose of levodopa after LCIG (LCIG plus oral control release); NA = not applicable; IQR = interquartile range.